Vaccine最新文献

{"title":"HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveys","authors":"Iacopo Baussano ,&nbsp;Vanessa Tenet ,&nbsp;Karina Baghdasarova ,&nbsp;Zaruhi Harutyunyan ,&nbsp;Alex Vorsters ,&nbsp;Daniëlle Heideman ,&nbsp;Maaike Bleeker ,&nbsp;Ricardo Rüttimann ,&nbsp;Gayane Sahakyan","doi":"10.1016/j.vaccine.2025.127405","DOIUrl":"10.1016/j.vaccine.2025.127405","url":null,"abstract":"<div><h3>Background</h3><div>In 2017, Armenia introduced a national human papillomavirus (HPV) vaccination programme with a quadrivalent vaccine at age 14 years. Successful implementation of the programme was affected by social media campaigns aiming to discredit its efficacy and safety, the COVID-19 pandemic, and local armed conflicts. To support national public health stakeholders, we initiated a series of studies to provide local evidence on the burden of HPV infection.</div></div><div><h3>Methods</h3><div>Two cross-sectional HPV prevalence surveys among unvaccinated birth-cohorts of women were conducted: a urine-based survey (UBS) targeted women aged 17–21 years, and a cell-based survey (CBS) targeted women aged 21–39 years. In addition, we collected a series of invasive cervical cancer (CC) case laboratory samples to assess the attributable proportion of high-risk (HR) HPV types to estimate the impact of HPV vaccination in Armenia.</div></div><div><h3>Findings</h3><div>In the UBS and the CBS, 2485 and 3017 women were included, respectively. In the UBS, 110 (4.5 %) women were positive for any HPV type, 72 (2.9 %) of which were HR HPV and 29 (1.2 %) were HPV16/18. In the CBS, 553 (18 %) were positive for any HPV type, 326 (11 %) of which were HR HPV, and 99 (3.3 %) were HPV16/18. In the CC series, HPV16/18 accounted for 71 % of all HR HPV infections, HPV 31, 33, 45, 52, and 58 accounted for an extra 18 %. The remaining HR types accounted for 11 % of all CC infected by HR HPV. The corresponding predicted cumulative 10-year CC incidence among 20–24, 25–34, and 35–44-year age group, was 0.3 %, 1.3 %, and 3.8 %, respectively.</div></div><div><h3>Interpretation</h3><div>Our findings provide a picture of the HPV infection and future cervical cancer burden among unvaccinated young and adult women in urban areas of Armenia and can inform context-specific vaccination and screening policies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127405"},"PeriodicalIF":4.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C","authors":"Timothy F. Spracklen ,&nbsp;Jonathan Day ,&nbsp;Hamza Van Der Ross ,&nbsp;Claire Butters ,&nbsp;Ntombi Benede ,&nbsp;Avril Walters ,&nbsp;Rubina Bunjun ,&nbsp;Thandeka Moyo-Gwete ,&nbsp;Mashudu Madzivhandila ,&nbsp;Simon C. Mendelsohn ,&nbsp;Thomas J. Scriba ,&nbsp;Muki Shey ,&nbsp;Wendy A. Burgers ,&nbsp;Penny L. Moore ,&nbsp;Liesl J. Zühlke ,&nbsp;Roanne S. Keeton ,&nbsp;Kate Webb","doi":"10.1016/j.vaccine.2025.127461","DOIUrl":"10.1016/j.vaccine.2025.127461","url":null,"abstract":"<div><div>The effects of SARS-CoV-2 vaccination in children with previous multisystem inflammatory syndrome (MIS-C) are not well understood. In this study, we aimed to assess immune responses to SARS-CoV-2 vaccination in children over the age of 12 years with previous MIS-C and compare them to healthy children. Three children with previous MIS-C and four healthy children received two doses of the BNT162b2 vaccine. Blood was collected before the first dose, one week after the first dose, one week after the second dose and three weeks after the second dose. All participants had detectable SARS-CoV-2 spike IgG before vaccination. Spike binding and neutralising antibody activity increased after the first vaccine dose with no differences between children with a history of MIS-C and healthy children. Serum inflammatory cytokines and whole blood immune gene profiles did not resemble acute MIS-C and there were no differences in these between the two groups at any timepoint. All participants gained a robust SARS-CoV-2-specific T cell response by three weeks after the second dose. A transient increase in SARS-CoV-2-specific CD4 T cells expressing TCR Vβ21.3, a non-specific T cell subset previously found to be enriched in patients with MIS-C, was demonstrated in two of the children with previous MIS-C but none of the healthy children. Together, these data demonstrate that vaccination is effective at boosting SARS-CoV-2-specific immune responses in a small group of children with previous MIS-C, and that it does not induce inflammatory cytokine or gene expression responses resembling acute MIS-C. Although larger-scale studies are needed to confirm these findings, the present evidence supports SARS-CoV-2 vaccination in children with previous MIS-C.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127461"},"PeriodicalIF":4.5,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influenza vaccine delivery models in secondary care (hospital) settings: What approaches are used to enhance access for clinical risk groups in England?","authors":"Rajeka Lazarus ,&nbsp;Ben Kasstan-Dabush ,&nbsp;Ifra Ali ,&nbsp;Sandra Mounier-Jack","doi":"10.1016/j.vaccine.2025.127445","DOIUrl":"10.1016/j.vaccine.2025.127445","url":null,"abstract":"<div><h3>Background</h3><div>Influenza vaccine uptake rates in England remain suboptimal among adults with clinical conditions that predispose to severe influenza. Influenza vaccines are predominantly delivered in primary care settings, but complementary delivery via a broader range of secondary care settings is recommended to enhance access. This qualitative study aimed to document current influenza vaccine delivery models in hospital-based settings and to compare the opportunities and limitations associated with those delivery models.</div></div><div><h3>Methods</h3><div>Semi-structured interviews (<em>n</em> = 28) were conducted with healthcare professionals based in secondary care, and with National Health Service commissioners to understand current vaccine delivery practices within hospital settings in two regions of England.</div></div><div><h3>Results</h3><div>Most hospitals who offered patient vaccination had invested in dedicated staff and processes to support influenza vaccine delivery. A variety of interventions were used to navigate the steps in the vaccination pathway. Challenges included engagement of medical staff, access to vaccination records and managing vaccine stocks.</div></div><div><h3>Conclusion</h3><div>Secondary care vaccination is possible with the appropriate investment in staff and processes. Focusing on staff engagement, addressing logistic challenges and providing adequate invesment would support the sustainability of vaccination in secondary care.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127445"},"PeriodicalIF":4.5,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Different patterns of antimicrobial non-susceptibility of the nasopharyngeal carriage of Streptococcus pneumoniae in areas with high and low levels of PCV13 coverage","authors":"Jian Wang ,&nbsp;Wei Zhao ,&nbsp;Shuang Bai ,&nbsp;Ao Zhang ,&nbsp;Junnan Zhang ,&nbsp;Wenwen Lan ,&nbsp;Yihan Zhang ,&nbsp;Jing Li ,&nbsp;Shanshan Zhou ,&nbsp;Qun Zheng ,&nbsp;Luodan Suo ,&nbsp;Min Lv ,&nbsp;Jiang Wu","doi":"10.1016/j.vaccine.2025.127455","DOIUrl":"10.1016/j.vaccine.2025.127455","url":null,"abstract":"<div><h3>Introduction</h3><div>The impact of pneumococcal conjugate vaccines (PCVs) on antimicrobial resistance (AMR) in <em>Streptococcus pneumoniae</em> (<em>Spn</em>) among Chinese children remains inadequately characterized. Evidence is also limited on the interaction between vaccination coverage and regional disparities in AMR patterns. This study aims to assess the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal carriage of <em>Spn</em> and antimicrobial nonsusceptibility to commonly used antibiotics among healthy children under five years of age in China.</div></div><div><h3>Methods</h3><div>In 2022, 737 pneumococci were isolated from 2333 healthy children recruited in 4 areas (Haikou, Wanning, Baisha, and Qiongzhong) in Hainan Province, China. Serotyping and antimicrobial susceptibility tests were performed. Participants were divided into 4 groups based on individual PCV13 vaccination history and the local vaccination coverage rates: vaccinated and unvaccinated groups in the high-coverage area (group VH &amp; NVH), and vaccinated and unvaccinated groups in the low-coverage areas (group VL &amp; NVL). Descriptive statistics and logistic regression analysis were used to assess the vaccine impacts.</div></div><div><h3>Results</h3><div>PCV13-vaccinated children exhibited significantly lower carriage rates of vaccine-type serotypes (VTs) compared to unvaccinated children: 6B (7.0 % vs. 2.7 %, P &lt; 0.01), 6A (4.2 % vs. 1.2 %, P &lt; 0.05), and 23F (2.2 % vs. 0.3 %, P &lt; 0.05). The non-susceptibility rates to erythromycin, azithromycin, clindamycin, tetracycline, penicillin, and cefuroxime were 92.3 %, 87.5 %, 81.2 %, 91.2 %, 38.9 % and 64.7 %, respectively, resulting in 82.9 % of isolates being multidrug-resistant (MDR), especially to VTs (92.4 %). Isolates from the high PCV13 coverage area were less resistant to penicillin, cefuroxime, erythromycin, azithromycin, clindamycin and SXT, and were less MDR than isolates from the low PCV13 coverage areas.</div></div><div><h3>Conclusions</h3><div>Nasopharyngeal carriage of <em>Spn</em> was highly resistant to common clinical antibiotics. PCV13 vaccination significantly decreased VTs carriage and antimicrobial nonsusceptibility. These results suggest that the widespread use of PCVs is likely to substantially affect NP carriage and antimicrobial nonsusceptibility.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127455"},"PeriodicalIF":4.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel liquid-phase blocking ELISA using single-domain antibody M8 and virus-like particles for in-vitro potency assessment of foot-and-mouth disease virus-like particle vaccine","authors":"Haozhou Li ,&nbsp;Aldo Dekker ,&nbsp;Yaya Zhang ,&nbsp;Yun Zhang ,&nbsp;Michiel Harmsen ,&nbsp;Wim van der Poel ,&nbsp;Huichen Guo ,&nbsp;Shiqi Sun","doi":"10.1016/j.vaccine.2025.127466","DOIUrl":"10.1016/j.vaccine.2025.127466","url":null,"abstract":"<div><div>Potency tests for inactivated foot-and-mouth disease (FMD) vaccines involve either <em>in vivo</em> challenge trials in target animals or <em>in vitro</em> tests. However, evaluating potency of FMD virus-like particle (VLP) vaccines currently lack <em>in vitro</em> tools. We developed a liquid-phase blocking ELISA (LPBE) using a broadly neutralizing single-domain antibody (M8) and FMD VLPs to assess antibody titers in animals vaccinated with FMD serotype O VLPs. We utilized 505 negative sera and 32 sera of pigs infected or vaccinated with other viruses than FMDV to validate the M8 LPBE detection limit. The M8 LPBE was compared to virus neutralizing test and conventional LPBE using 338 sera from PD₅₀ potency tests in cattle and pigs. The results were analyzed using logistic models. The M8 LPBE showed superior correlation with protection, with an average titer of 1.7 log₁₀ corresponding to a potency of 3 PD₅₀/dose.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127466"},"PeriodicalIF":4.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing the uptake of Live Attenuated Influenza Vaccine through a new school-based vaccination programme in Ireland","authors":"James Gilroy ,&nbsp;Maureen O'Leary ,&nbsp;Lisa Domegan ,&nbsp;Lois O'Connor ,&nbsp;Caralyn Horne ,&nbsp;Aparna Keegan ,&nbsp;Alice Quinn ,&nbsp;Eimear Hayes ,&nbsp;Louise Marron","doi":"10.1016/j.vaccine.2025.127467","DOIUrl":"10.1016/j.vaccine.2025.127467","url":null,"abstract":"<div><h3>Background</h3><div>Influenza vaccination is an important and effective public health intervention. Since 2020, live attenuated influenza vaccine (LAIV) has been available for children in Ireland, provided in the community in primary care. However, vaccine uptake has been suboptimal. Offering influenza vaccination in schools has improved uptake in other countries. In the 2023/24 influenza season, LAIV was offered in schools in Ireland, to targeted school year groups.</div></div><div><h3>Aim</h3><div>To evaluate the LAIV schools programme in the 2023/24 influenza season in Ireland, by estimating vaccine uptake and identifying factors associated with vaccine uptake.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study. Mobile school vaccination teams collected demographic and vaccine uptake data. Univariable and multivariable regression analyses examined if school type, school size and programme resources were associated with differences in vaccine uptake.</div></div><div><h3>Results</h3><div>Offering LAIV to children in target school year groups in 1537 schools in Ireland resulted in a mean vaccine uptake of 49.3 %, compared to the general community uptake of 16.2 % in children aged 2–17 years. Vaccine uptake was lower in schools with higher proportions of children at risk of educational disadvantage (adjusted difference in means 8.0 %, 95 % CI 5.45 %–10.5 %). Larger schools had lower vaccine uptake, with each 10-child increase in enrolment associated with a 1.2 % adjusted decrease in mean uptake (95 % CI 0.7 % to 1.8 %).</div></div><div><h3>Conclusion</h3><div>Offering LAIV in a school setting in Ireland resulted in a higher vaccine uptake than the general community uptake in children. This study supports the use of a schools-based approach for influenza vaccination. Additional supports may be required to improve uptake in children at risk of educational disadvantage and those with complex needs.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127467"},"PeriodicalIF":4.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons learnt during establishment of COVID-19 active vaccine safety surveillance in nine African countries","authors":"Clare L. Cutland ,&nbsp;Kimberley Gutu ,&nbsp;Jessica Ann Yun ,&nbsp;Alane Izu ,&nbsp;Sana Mahtab ,&nbsp;Jonny Peter ,&nbsp;Nana Akosua Ansah ,&nbsp;Stephen Obaro ,&nbsp;Binyam Tilahun ,&nbsp;Kondwani Jambo ,&nbsp;Samba Sow ,&nbsp;Eunice Wangeci Kagucia ,&nbsp;Sergio Chicumbe ,&nbsp;Tenelisiwe Dlamini ,&nbsp;Michael Browne ,&nbsp;Hazel Clothier ,&nbsp;Jennifer Griffin ,&nbsp;Yannan Jiang ,&nbsp;Arier Lee ,&nbsp;Luam Ghebreab ,&nbsp;Esperanca Sevene","doi":"10.1016/j.vaccine.2025.127441","DOIUrl":"10.1016/j.vaccine.2025.127441","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Globally, several gaps in vaccine safety surveillance exist, particularly in low- and middle- income countries (LMICs). Establishing and maintaining vaccine surveillance platforms in resource-constrained settings poses significant challenges. These countries often rely on paper-based medical records and immunization cards, lack unique patient identifiers across the healthcare systems, have limited electronic data capture capabilities, and face a shortage of clinical reviewers for case assessments.&lt;/div&gt;&lt;div&gt;This report highlights the establishment of two active vaccine safety surveillance studies across nine African countries: (i) &lt;strong&gt;A&lt;/strong&gt;ctive &lt;strong&gt;C&lt;/strong&gt;OVID-19 &lt;strong&gt;va&lt;/strong&gt;ccine &lt;strong&gt;s&lt;/strong&gt;afety &lt;strong&gt;s&lt;/strong&gt;urveillance (ACVaSS) in eight COVAX 92 Advanced Market Commitment (AMC-92) eligible African countries including Ethiopia, Ghana, Kenya, Mali, Malawi, Mozambique, Nigeria and Eswatini and (ii) the &lt;strong&gt;S&lt;/strong&gt;outh &lt;strong&gt;A&lt;/strong&gt;frican &lt;strong&gt;C&lt;/strong&gt;OVID-19 &lt;strong&gt;v&lt;/strong&gt;accine &lt;strong&gt;s&lt;/strong&gt;afety &lt;strong&gt;s&lt;/strong&gt;urveillance study (SA-CVSS).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Both ACVaSS and SA-CVSS were hospital-based sentinel active surveillance studies designed to monitor the safety of COVID-19 vaccines in the aforementioned COVAX AMC-92 countries and South Africa, a middle-income African country. Patients presenting to healthcare facilities with illnesses resembling pre-selected adverse events of special interest (AESIs), were enrolled, with informed consent, into the studies. The Brighton Collaboration Case Definitions were applied to classify AESIs.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Over 60,000 admitted patients were screened and over 12,700 eligible patients were enrolled in 18 months. Despite challenges in accessing and abstracting data from predominantly paper-based medical and vaccination records, the identification of specific AESIs and estimating association with vaccination status was feasible in LMIC healthcare facilities.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;The establishment of active vaccine safety surveillance sentinel sites is achievable in LMICs, though the lack of digital medical records hindered data accessibility and availability. Regulatory authorities, health departments and organizations supporting immunization programs must prioritize the development, maintenance and funding of active vaccine safety surveillance systems. Such surveillance is crucial to ensuring that new vaccines are properly monitored and assessed for safety following their introduction and use in these populations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;The SA-CVSS study was funded by a US CDC Grant to the GVDN (grant reference: CDC Funder Award Number: 1 NU38CK000485–01-00), the South African Medical Research Council (SAMRC) and the Task Force for Global Health (RVD_CDC-COV). Gavi, The Vaccine Alliance, funded the ACVaSS study (Agreement reference: MEL","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127441"},"PeriodicalIF":4.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multifaceted, targeted intervention to improve human papillomavirus vaccination rates in general practice: A pragmatic cluster-randomized controlled trial","authors":"Andreas Plate,&nbsp;Levy Jäger,&nbsp;Stefania Di Gangi,&nbsp;Giuseppe Pichierri,&nbsp;Thomas Grischott,&nbsp;Thomas Lutz,&nbsp;Thomas Rosemann,&nbsp;Oliver Senn","doi":"10.1016/j.vaccine.2025.127444","DOIUrl":"10.1016/j.vaccine.2025.127444","url":null,"abstract":"<div><h3>Background</h3><div>Human papillomavirus (HPV) vaccination rates are low in Switzerland. The aim of the study was to test a pragmatic multifaceted targeted intervention among general practitioners (GPs) to increase HPV vaccination (HPVv) rates in general practice.</div></div><div><h3>Methods</h3><div>In this cluster-randomized controlled trial, two equally sized groups of GPs each received an educational session on vaccination in general and on the national vaccination schedule. Treatment group GPs additionally received detailed information about HPV, information leaflets, and were instructed on HPV announcement training as an approach to recommend HPVv. Primary outcome was the number of first HPVv doses administered per GP up to six months after study start (T6). Secondary outcomes were first HPVv dose counts at T3 and T12 and the GPs' changes in attitudes and knowledge regarding HPVv from baseline to T6. Outcomes were analysed using mixed-effects Poisson and logistic regression models.</div></div><div><h3>Results</h3><div>A total of <em>N</em> = 56 practices with <em>n</em> = 72 GPs were randomized. GPs administered a total of 5329 vaccine doses including 195 HPVv doses. The intervention had no effect on the primary outcome (adjusted rate ratio [95 % CI]: 1.55 [0.72–3.37]), and none of the secondary HPVv count outcomes reached statistical significance. The treatment group showed significantly higher odds of changing attitudes towards HPVv (adjusted odds ratio [95 % CI]: 17.89 [3.36–95.23]). We found no difference in knowledge gain between the groups.</div></div><div><h3>Conclusion</h3><div>The multifaceted intervention improved attitudes towards HPVv but failed to increase HPVv rates or knowledge. Insights from the study can help inform the development of future HPVv interventions.</div></div><div><h3>Trial registration</h3><div>ISRCTN 55473884, first registered on 04/06/2021.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127444"},"PeriodicalIF":4.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of shingles vaccine tolerability on initiation and completion of the two-dose series in adults 50 years and older","authors":"Abram L. Wagner,&nbsp;Christopher Floyd","doi":"10.1016/j.vaccine.2025.127465","DOIUrl":"10.1016/j.vaccine.2025.127465","url":null,"abstract":"<div><div>Shingles is a painful disease, commonly affecting older adults, and caused by the reactivation of the Varicella Zoster Virus (VZV). The currently available recombinant zoster vaccine, brand name Shingrix (SHX), has relatively low uptake. This study aimed to quantify the possible impact on initiation and completion of the two-dose SHX series related to concerns of SHX side effects among adults aged 50 and older. We implemented both a nationally representative sample in the US (<em>N</em> = 1004) and a hospital-based sample from Michigan (<em>N</em> = 566). In the national sample, 206 (17 %, 95 % CI: 14 %, 20 %) respondents had 2 doses of SHX, 52 had 1 dose (4 %, 95 % CI: 3 %, 5 %), and 555 (61 %) were unvaccinated (95 % CI: 57 %, 65 %). In the Michigan sample, concerns about tolerability were significantly associated with the number of SHX doses received (<em>p</em> &lt; 0.0001). Among those who had not received any doses, 46 % reported being concerned about tolerability, compared to 39 % among those with 1 dose, and only 22 % of those who had received two doses. Individuals concerned about side effects were 1.22 times more likely to not receive any dose (95 % CI: 1.11, 1.34), and 1.83 times more likely to receive only one dose (95 % CI: 1.26, 2.65) than to receive the full two dose series. That tolerability was the leading reason for both initiation and completion of the SHX vaccine series underscores the need for increased attention on perceptions about vaccine tolerability, as separate from safety, in the introduction and promotion of vaccines. Addressing concerns about vaccine tolerability could improve SHX coverage, ultimately reducing the burden of shingles in older populations.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127465"},"PeriodicalIF":4.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns","authors":"Melanie M. Schmitt ,&nbsp;Annika Rössler ,&nbsp;Antonia Netzl ,&nbsp;Ludwig Knabl ,&nbsp;Albert Falch ,&nbsp;Patrick Neckermann ,&nbsp;Marta Bermejo-Jambrina ,&nbsp;Wegene Borena ,&nbsp;Gagandeep Singh ,&nbsp;Florian Krammer ,&nbsp;Dorothee von Laer ,&nbsp;Ralf Wagner ,&nbsp;Derek J. Smith ,&nbsp;Janine Kimpel","doi":"10.1016/j.vaccine.2025.127459","DOIUrl":"10.1016/j.vaccine.2025.127459","url":null,"abstract":"<div><div>Previous exposure to one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant influences neutralizing antibody responses induced by subsequent exposures. Consecutive exposures predominantly back-boost pre-existing immunity and expand cross-neutralizing antibodies while de novo variant-specific responses are poorly induced. In this study, we analyzed neutralizing antibodies against a panel of variants in plasma samples from individuals after exactly two exposures: twice pre-Omicron variant (either two dose vaccinated or infected and one dose vaccinated), pre-Omicron followed by early Omicron variant, or twice early Omicron variant. We found that exposure to two antigenically distinct variants, either pre-Omicron followed by Omicron or two different Omicron variants, increased the neutralization breadth. However, no significant cross-neutralization against the genetically closely related human coronavirus SARS-CoV was induced. Using depletion experiments, we showed that the first exposed variant strongly influences the specificity of antibodies. The second exposure primarily expanded cross-reactive antibodies rather than inducing a variant-specific response against the later variant, highlighting the phenomenon of immune imprinting in the context of SARS-CoV-2. Overall, our results indicate that multiple exposures to SARS-CoV-2 improve cross-neutralization against a variety of variants, but also underscore the lack of de novo antibody production against the more recently encountered variant.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127459"},"PeriodicalIF":4.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}